Literature DB >> 23928950

Fellow Eye Comparison of Descemet Membrane Endothelial Keratoplasty and Penetrating Keratoplasty.

Anna-Karina B Maier1, Enken Gundlach, Johannes Gonnermann, Matthias K J Klamann, Christian Eulufi, Eckart Bertelmann, Antonia M Joussen, Necip Torun.   

Abstract

PURPOSE: To compare the visual outcomes and postoperative complications in patients undergoing penetrating keratoplasty (PKP) in 1 eye followed by Descemet membrane endothelial keratoplasty (DMEK) in their fellow eye.
METHODS: A retrospective analysis of 11 patients, who underwent a PKP procedure first in 1 eye and then a DMEK surgery in their fellow eye, was performed. Intraoperative and postoperative complications were recorded. Visual and refractive outcomes were also evaluated, including higher-order aberrations (HOAs) and contrast thresholds. A subjective questionnaire was used to evaluate patient satisfaction.
RESULTS: Both uncorrected and best-corrected visual acuities were significantly better in the case of DMEK when compared with that in the case of PKP (0.82 vs. 0.37 logMAR, P = 0.005; 0.61 vs. 0.21 logMAR, P = 0.011, respectively). Postkeratoplasty astigmatism, mean spherical equivalent, and HOAs were also significantly lower in eyes after undergoing DMEK than after undergoing PKP (3.90 vs. 0.89 diopters, P = 0.005; -3.90 vs. -0.68 diopters, P = 0.005; 6.81 vs. 1.71 µm, P = 0.043, respectively). Visual outcome and patient satisfaction were significantly better in those who underwent DMEK (2.91 vs. 4.45, P = 0.011; 3.27 vs. 5.64, P = 0.016, respectively). The estimated time for recovery and rehabilitation was significantly shorter after DMEK (64.0 vs. 9.3 days, P = 0.012). Contrast threshold was better after the DMEK. Ten of 11 patients preferred DMEK procedure.
CONCLUSIONS: The Patients preferred DMEK to PKP. The reasons for better patient satisfaction after DMEK included better uncorrected visual acuity, better best-corrected visual acuity, avoidance of surgery-induced astigmatism, and lower HOA.

Entities:  

Mesh:

Year:  2013        PMID: 23928950     DOI: 10.1097/ICO.0b013e31829dd816

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  7 in total

1.  Outcomes of Descemet membrane endothelial keratoplasty, Descemet stripping automated endothelial keratoplasty and penetrating keratoplasty from a single centre study.

Authors:  S Heinzelmann; D Böhringer; P Eberwein; T Reinhard; P Maier
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-07       Impact factor: 3.117

2.  3D in vitro model for human corneal endothelial cell maturation.

Authors:  Audrey E K Hutcheon; James D Zieske; Xiaoqing Guo
Journal:  Exp Eye Res       Date:  2019-04-10       Impact factor: 3.467

3.  Descemet membrane endothelial keratoplasty for graft failure following penetrating keratoplasty.

Authors:  Sonja Heinzelmann; Daniel Böhringer; Philipp Eberwein; Thabo Lapp; Thomas Reinhard; Philip Maier
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-03       Impact factor: 3.117

4.  [Perforating keratoplasty versus Descemet stripping automated endothelial keratoplasty in the partner eye: Functional results and patient satisfaction].

Authors:  N J Gross; D Böhringer; P Maier; T Reinhard
Journal:  Ophthalmologe       Date:  2015-10       Impact factor: 1.059

5.  Impact of DMEK on visual quality in patients with Fuchs' endothelial dystrophy.

Authors:  Vanessa Ademmer; Bishr Agha; Mehdi Shajari; Thomas Kohnen; Ingo Schmack
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-16       Impact factor: 3.535

6.  Refractive outcome and tomographic changes after Descemet membrane endothelial keratoplasty in pseudophakic eyes with Fuchs' endothelial dystrophy.

Authors:  Bishr Agha; Nura Ahmad; Daniel G Dawson; Thomas Kohnen; Ingo Schmack
Journal:  Int Ophthalmol       Date:  2021-06-29       Impact factor: 2.031

7.  Influence of rebubbling on anterior segment parameters and refractive outcomes in eyes with DMEK for Fuchs endothelial dystrophy.

Authors:  Bishr Agha; Raimund Forster; Thomas Kohnen; Ingo Schmack
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-04-06       Impact factor: 3.117

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.